Boston University School of Medicine, Boston, MA, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
J Diabetes Sci Technol. 2022 Jul;16(4):995-1002. doi: 10.1177/1932296821997923. Epub 2021 Mar 5.
Diabetes is an increasing public health problem, and insulin is the mainstay for treatment of type 1 diabetes. In type 2 diabetes treatment, insulin therapy is used after oral or other injectable agents become inadequate to achieve glycemic control. Despite the advances in insulin therapy, management of diabetes remains challenging. Numerous studies have reported low adherence and persistence to insulin therapy, which acts as a barrier to successful glycemic control and diabetes management. The aim of this targeted review article is to provide an overview of adherence and persistence to insulin therapy in people with diabetes and to discuss the impact of the emergence of a new connected ecosystem of increasingly sophisticated insulin pens, glucose monitoring systems, telemedicine, and mHealth on diabetes management. With the emergence of a connected diabetes ecosystem, we have entered an era of advanced personalized insulin delivery, which will have the potential to enhance diabetes self-management and clinical management. Early systems promise to unlock the potential to address missed or late bolus insulin delivery, which should help to address non-adherence and non-persistence. Over time, improvements in this ecosystem have the potential to combine insulin data with previously missing contextualized patient data, including meal, glucose, and activity data to support personalized clinical decisions and ultimately revolutionize insulin therapy.
糖尿病是一个日益严重的公共卫生问题,胰岛素是治疗 1 型糖尿病的主要药物。在 2 型糖尿病的治疗中,当口服或其他注射药物不足以控制血糖时,会采用胰岛素治疗。尽管胰岛素治疗取得了进展,但糖尿病的管理仍然具有挑战性。许多研究报告称,糖尿病患者对胰岛素治疗的依从性和持久性较低,这是成功控制血糖和管理糖尿病的障碍。本文旨在概述糖尿病患者对胰岛素治疗的依从性和持久性,并讨论新出现的日益复杂的胰岛素笔、血糖监测系统、远程医疗和移动医疗等新型互联生态系统对糖尿病管理的影响。随着互联糖尿病生态系统的出现,我们已经进入了先进的个性化胰岛素输送时代,这将有可能增强糖尿病的自我管理和临床管理。早期系统有望解决错过或延迟注射胰岛素的问题,从而有助于解决不依从和不持久的问题。随着时间的推移,该系统有望将胰岛素数据与之前缺失的上下文化患者数据(包括膳食、血糖和活动数据)相结合,以支持个性化的临床决策,并最终彻底改变胰岛素治疗。